Genmab sales of Darzalex exceed expectations in Q3
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13382802.ece/ALTERNATES/schema-16_9/doc7i18sivq91ffrd1c4pz.jpg)
The Genmab-developed treatment for multiple myeloma, a type of bone marrow cancer, has exceeded expectations in the third quarter of the year, according to Q3 reports from Johnson & Johson, which obtained the drug through an in-licensing agreement.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Janssen had better Darzalex sales than expected in Q1
For subscribers
Genmab CEO: Arbitration might be concluded in 2021
For subscribers